Abstract
Avitinib is an oral, potent, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor selective for the EGFR T790 M mutation. We report the safety, intra-/extracranial efficacy, and the blood-brain barrier (BBB) penetration rate of avitinib (NCT02330367). Non-small cell lung cancer (NSCLC) patients with the EGFR T790 M mutation were orally administered avitinib (150-300 mg) twice daily for cycles of 28 continuous days. Blood and cerebrospinal fluid samples (2 ml each) were collected on day 29 in available patients with brain metastases, and the tumor response was assessed. Sixteen NSCLC patients were included, of whom nine (60.0%) achieved a partial response, and five (33.3%) achieved stable disease. Median progression-free survival (PFS) and overall survival were 247 days (95% confidence interval (CI): 154.8-339.2) and 536 days (95%CI: 363.6-708.4), respectively. The median intracranial PFS of seven brain metastases patients was 142 days (95% CI 31.1-252.9). Blood and cerebrospinal fluid analysis of five brain metastases patients showed the BBB penetration rate to be 0.046%-0.146%. The most frequent adverse events were mild and reversible hepatic transaminases elevating (10/16, 62.5%) and diarrhea (4/16, ...Continue Reading
References
Jan 18, 2003·Vascular Pharmacology·Michel DemeuleRichard Béliveau
Apr 14, 2005·Molecular Cancer Therapeutics·David McKillopTrevor C Stephens
Apr 22, 2005·Cancer·Antonio M P OmuroLauren E Abrey
Jun 16, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Takeshi KitazakiShigeru Kohno
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Dec 22, 2009·The Lancet Oncology·Tetsuya MitsudomiUNKNOWN West Japan Oncology Group
Jan 29, 2011·Cancer Chemotherapy and Pharmacology·Takeshi MasudaNobuoki Kohno
Feb 26, 2011·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayDonald Maxwell Parkin
Jun 15, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Masahiro FukuokaTony S K Mok
Jul 26, 2011·The Lancet Oncology·Caicun ZhouChangxuan You
Aug 26, 2011·Neuro-oncology·Christian GrommesAndrew B Lassman
Jan 31, 2012·The Lancet Oncology·Rafael RosellUNKNOWN Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia T
Jan 25, 2013·International Journal of Molecular Sciences·Imola WilhelmIstván A Krizbai
Mar 9, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Helena A YuGregory J Riely
Aug 21, 2013·The Lancet Oncology·Yuankai ShiYan Sun
Sep 10, 2013·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Yan ChenJing Zhao
Jul 22, 2014·Molecular Membrane Biology·Marta TajesFrancisco J Muñoz
Sep 24, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Petra HoffknechtUNKNOWN Afatinib Compassionate Use Consortium (ACUC)
Apr 30, 2015·Cancer Chemotherapy and Pharmacology·Takahisa KawamuraNobuyuki Katakami
Aug 4, 2016·Oncotarget·Guang HanWeining Zhen
Aug 19, 2016·SpringerPlus·Xu YufenYang Xinmei
Dec 14, 2016·The New England Journal of Medicine·Tony S MokUNKNOWN AURA3 Investigators
Mar 13, 2017·Journal of Pharmaceutical and Biomedical Analysis·Weicong WangPei Hu
Citations
Sep 13, 2019·Bioscience Trends·Xu YaoJianjun Gao
Jan 17, 2020·Thoracic Cancer·Hanping WangLi Zhang
Oct 31, 2020·Current Opinion in Oncology·Lingyun YeFei Zhou
Aug 21, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ligang XingJinming Yu
Mar 30, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Rui-Fang DongLing-Yi Kong
Jul 28, 2021·European Journal of Medicinal Chemistry·Zhenqiang XiaYang He
Aug 28, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Yuan LiangJie Zhang
Aug 3, 2021·Journal of Biomolecular Structure & Dynamics·Fangfang WangBo Zhou